Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement,”Annals of Surgical Oncology

States will undergo resection of pancreatic cancer with curative intent. Despite concerted international efforts, especially over the past 20 years, survival statistics for such patients have changed little and remain disappointing. Reported 2- and-5 year overall survival rates for patient with resected pancreas cancer are 40–50 % and 15–20%, respectively, and rates of local and systemic recurrence also remain high—35–60 % and 80–90%, respectively.1–7 Considerable debate surrounds the best therapeutic approach for such patients. Efforts to increase the number of long-term survivors after curative-intent pancreas cancer resection have to date cen-tered on one of four areas: (1) neoadjuvant therapy before surgery, (2) adjuvant chemotherapy, (3) whether or not to include radiation treatment, and (4) the extension of poten-tially curative treatment to patients with borderline resectable disease. While we acknowledge the controversies and complexities associated with each of these four areas, as well as the limitations of available data, our goal here is to articulate working consensus statements that provide focus for future study and express present levels of agreement